Hanlan Liu

WORK HISTORY

EDUCATION

ABOUT HANLAN LIU

Broad knowledge and experience of drug R&D process including preparation of 6 INDs, and 5 product submissions and/or post market drug life cycle dossiers, and 7 patents Significant roles with Clofarabin®, Hectorol®, Mozobil®, Mipomerson®, Cerdelga®, Venglustat (Phase II), and Edasalonexent (Phase nonclinical and clinical development in DMPK, bioanalysis, and clinical pharmacology Core team member of 30+ drug discovery and development projects in the rare genetic diseases including lysosomal storage disorders, neuromuscular disorders, cystic fibrosis, as well as oncology, immunology, and immuno-oncology, 8 of which advanced to clinic trials. 23 years of combined large pharmaceutical, biotechnology, and start-up company experiences ranging from discovery, nonclinical research and development, and Phase 1 to Phase 3 clinical development (e.g, INTERACT, IND, IB, EOP2, SAWP, NDA, EMEA) Leadership skills evident at multi-discipline functional teams as project co-leaders and in complicated settings Success in US, European, and Japanese pharmaceutical, large and small biotechnology, for-profit and non-profit organizations Strategic thinker with can-do attitude, value-driven, business acumen, and optimism Regarded as an industry scientific expert in drug metabolism and pharmacokinetics Chair of New England Drug Metabolism Discussion Group Steering Committee composed of senior DMPK leaders from 19 big pharmaceutical and biotech companies from the Boston ecosystem Author of 33 publications in peer-reviewed journals Inventor of 7 patents Invited speaker or presenter of 59+ posters at scientific conferences